Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology IncfiledCriticalLoxo Oncology Inc
Priority to JOP/2017/0191ApriorityCriticalpatent/JOP20170191A1/en
Publication of JOP20170191A1publicationCriticalpatent/JOP20170191A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Investigating Or Analysing Biological Materials
(AREA)
Abstract
A variety of different point mutations in NTRK1, NTRK2, and NTRK3 were identified in biopsy samples from a subjects having a variety of different cancers. Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment including a therapeutically effective amount of a Trk inhibitor for a subject, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having a cancer, methods of determining a subject’s risk for developing a cancer, and methods of assisting in the diagnosis of cancer that are based on the identification of a subject having a cell that has at least one of the point mutations in NTRK1, NTRK2, and/or NTRK3, or the determination that a subject has a cell that has at least one of the point mutations in NTRK1, NTRK2, and/or NTRK3. Also provided are kits that allow for the detection of at least one of the point mutations in NTRK1, NTRK2, and/or NTRK3.
JOP/2017/0191A2017-12-032017-12-03Methods of diagnosing and treating cancer
JOP20170191A1
(en)
METHODS FOR TAGGING EURARIOTIC CELLS OF A MULTICELLULAR ORGANISM, AND ALSO TREATMENT AND / OR DIAGNOSIS OF CANCER USING MODIFIED MONOSACCHARIDE COMPOUNDS